Figure 5.
Immunization of mice with 12B1-derived CRCL-loaded DCs provides superior therapeutic effects. BALB/c mice were injected with 3 × 103 12B1 cells subcutaneously in the right groin on day 0. On day 2, mice were immunized with 5 × 105 DCs that had been loaded with 12B1-derived CRCL or indicated peptides as mentioned in “Materials and methods.” Survival of mice was monitored and displayed in the Kaplan-Meier plot (n = 8-16 mice per group; pooled data from 2 experiments are shown). PBS versus DC/CRCL, P < .05; PBS versus DC/BCR-ABL peptide, P < .05; DC/irrelevant peptide versus DC/CRCL, P < .05; DC/irrelevant peptide versus DC/BCR-ABL peptide, P < .05; DC/CRCL versus DC/BCR-ABL, P < .05.
